✨ Medicines Act Notices




1832 NEW ZEALAND GAZETTE No. 69

Health

Medicines Act 1981

Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Atovaquone 250 mg Tablet Wellcome Foundation Limited, Temple Hill, Dartford, Kent, United Kingdom Wellvone

Note: This medicine may only be distributed, supplied, or used under conditions to be imposed from time to time by the Director-General of Health.

Dated this 9th day of July 1995.

DAVID SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

g03587

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Flucloxacillin sodium equivalent to 250 mg, 500 mg or 1 g flucloxacillin Powder for injection (vials) CT Laboratorio, San Remo, Italy and IBSA SA, Lugano, Switzerland Flucloxacillin for injection
Vincristine sulphate 1 mg/mL in 1 mL, 2 mL and 5 mL Solution for IV injection (vials) Delta West Pty Limited, Bentley, Western Australia, Australia Vincristine Sulphate Injection
Methadone hydrochloride 5 mg/5 mL in 200 mL and 1000 mL Syrup Wellcome Australia Limited, Cabarita, New South Wales, Australia Methadone
Miconazole nitrate 2.5 mg/g, zinc oxide 150 mg/g in 15 g Ointment Janssen Pharmaceutica nv., Beerse, Belgium Daktozin
Isofluorane 100% in 100 mL Liquid (volatile inhalant) Ohmeda Caribe Inc., Guayama, Puerto Rico Aerrane
Pethidine hydrochloride 50 mg, 100 mg Tablet Douglas Pharmaceuticals Limited, Mount Roskill, Auckland

Note: Not to be marketed as substitutable for any other pethidine hydrochloride product as if the two (2) products were bioequivalent.

Dated this 9th day of July 1995.

DAVID SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

g04585

Consent to the Distribution of a New Related Product

Pursuant to section 96 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new related product set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name
Potassium nitrate 50 mg, sodium fluoride 2.25 mg per gm Toothpaste Packaging Corporation of America, Los Angeles, California, United States of America and Chempac Liquid, Division of CCL Industries, Etobicoke, Ontario, Canada Oral-B Sensitive with Fluoride


Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1995, No 69


NZLII PDF NZ Gazette 1995, No 69





✨ LLM interpretation of page content

πŸ₯ Provisional Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
9 July 1995
Medicines Act, Provisional Consent, Atovaquone, Wellvone
  • DAVID SMYTH, Acting Director-General of Health

πŸ₯ Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
9 July 1995
Medicines Act, Consent to Distribution, Flucloxacillin, Vincristine, Methadone, Miconazole, Isofluorane, Pethidine
  • DAVID SMYTH, Acting Director-General of Health

πŸ₯ Consent to the Distribution of a New Related Product

πŸ₯ Health & Social Welfare
9 July 1995
Medicines Act, Consent to Distribution, Potassium nitrate, sodium fluoride, Oral-B Sensitive with Fluoride
  • DAVID SMYTH, Acting Director-General of Health